Following up, it would be a big problem if the company kept saying positive things about the drug if it is not certain -- if the trial results is ambiguous.
Excellent points, thank you, and couple the fact that he's making disclosed insider purchases WITH THE FACT that they've made it clear in the August SEC filing that they are moving forward with a new Ph2/3 trial for Alzheimer's, and it would even more-so be considered potentially misleading IF the extension trial data was poor/disappointing to date.
Dr M has previously stated that they've designed the trials to fail quickly; for compassionate considerations of the participants and caregivers I believe.
Would he press on to a confirmatory ph2/3 with hundreds of participants IF extension data was poor/disappointing?
News 
Market Data 
Discover 
